Investor news Investor newsFinancial reportsInvest in InifyCompany overviewCorporate governanceExecutive teamBoard of directorsSustainabilityThe shareFinancial calendarContactsSubscription All2024202320222021Annual General MeetingPrimary Insider Transactions2024-11-15Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million2024-11-15Inify Laboratories - notice of Extraordinary General Meeting on December 6, 20242024-11-05Inify Laboratories enter a research partnership with the Department of Molecular Medicine and Surgery at Karolinska Institutet aiming to advance precision diagnostics within prostate cancer2024-10-25Panel talk about Inify’s third quarter 20242024-10-23Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics2024-09-09Panel talk about Inify’s second quarter 20242024-08-21INIFY Laboratories: 62% revenue growth and strong international interest2024-05-15Inify Laboratories AB (publ) – summary of Annual General Meeting2024-04-24Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 20232024-04-24Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 20232024-04-11Inify Laboratories - Annual Report 20232024-04-11Inify Laboratories – notice of Annual General Meeting on May 14, 20242024-03-05Panel talk about Inify’s fourth quarter 20232024-02-29Foresees a noticeable increase of customers, volume, and sales in 20242023-11-06Inify Laboratories receives accreditation as a medical laboratory2023-10-24Panel talk about Inify’s third quarter 20232023-10-24Continuous diagnostic operation and very positive feedback from customers2023-08-28Panel talk about Inify’s second quarter 20232023-08-23Inify Laboratories - Successful laboratory launch in Q2 with delivery of first prostate cancer diagnosis2023-07-05Inify Laboratories - mandatory notification of trade2023-06-20Successful launch of Inify Laboratories’ services, with first patient cases diagnosed2023-05-17Inify Laboratories AB (publ) – summary of Annual General Meeting2023-04-26Inify Laboratories - Strong market interest and launch on track2023-04-12Inify Laboratories - Annual Report 20222023-04-12Inify Laboratories - notice of Annual General Meeting on May 16, 20232023-02-23Panel talk about Inify’s fourth quarter 20222023-02-22Inify Laboratories - Ultramodern AI-based digital pathology laboratory completed in record time2022-11-09Panel talk about Inify’s third quarter2022-10-26Inify Laboratories - Laboratory and recruitment on track with positive market feedback2022-08-30Inify Laboratories AB (publ) – Extraordinary General Meeting2022-08-19Inify Laboratories – mandatory notification of trade2022-08-17Inify’s first ultramodern laboratory on track2022-07-28Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)2022-07-28Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)2022-06-29Inify Laboratories announces the appointment of Chief Medical Officer (CMO)2022-06-20Inify Laboratories – now listed on Euronext Growth in Oslo under the INIFY ticker2022-06-16Inify Laboratories – Decision on admission to trading – Euronext Growth Oslo2022-05-30Inify Laboratories – Extended subscription period2022-05-09Inify Laboratories – extra bolagsstämma 2022-05-092022-04-11Inify Laboratories – kallelse till extra bolagsstämma2021-12-10Inify Laboratories AB becomes an independent company2021-11-15ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service2021-10-21Aiming to build the company’s first modern pathology lab